Effient vs Eliquis: Distinct Indications for Different Clinical Scenarios
Effient (prasugrel) and Eliquis (apixaban) are fundamentally different medications used for entirely separate clinical indications and should never be considered interchangeable. Effient is an antiplatelet agent (P2Y12 inhibitor) indicated for acute coronary syndromes with planned percutaneous coronary intervention, while Eliquis is an anticoagulant (factor Xa inhibitor) indicated for atrial fibrillation stroke prevention and venous thromboembolism treatment.
Effient (Prasugrel) Indications
Effient is specifically indicated for patients with acute coronary syndromes (unstable angina, NSTEMI, or STEMI) who are undergoing percutaneous coronary intervention (PCI). 1
Primary Use in ACS with PCI
- Prasugrel should be administered as a 60 mg loading dose at the time of PCI, once coronary anatomy is defined and a decision to proceed with PCI is made, followed by 10 mg daily maintenance 2, 3
- For NSTEMI/unstable angina patients, prasugrel demonstrated superior efficacy compared to clopidogrel, reducing cardiovascular death, MI, and stroke from 12.1% to 9.9% (HR 0.81, P<0.001) 4, 5
- Prasugrel significantly reduced stent thrombosis rates from 2.4% to 1.1% (P<0.001) compared to clopidogrel 4
Critical Contraindications for Prasugrel
Prasugrel is absolutely contraindicated in patients with prior stroke or TIA due to increased risk of intracranial hemorrhage. 4, 6, 1
- In patients with prior TIA/stroke, prasugrel caused stroke in 6.5% (including 2.3% intracranial hemorrhage) versus 1.2% with clopidogrel 1
- Prasugrel is generally not recommended for patients ≥75 years due to increased fatal and intracranial bleeding risk, except in high-risk situations (diabetes or prior MI) where benefit may outweigh risk 4, 1
- Consider dose reduction to 5 mg daily for patients weighing <60 kg due to increased bleeding risk 3, 1
Timing Considerations
Pretreatment with prasugrel before coronary angiography is NOT recommended in NSTE-ACS. 7
- The ACCOAST trial demonstrated that pretreatment with prasugrel did not reduce ischemic events but increased TIMI major bleeding by 90% (HR 1.90, P=0.006) 7
- Prasugrel should be given only after coronary anatomy is known and PCI is planned 2, 8
Eliquis (Apixaban) Indications
Eliquis is an oral anticoagulant indicated for stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism. It has no role in acute coronary syndrome management as monotherapy.
Primary Indications
- Stroke prevention in non-valvular atrial fibrillation 9
- Treatment and prevention of deep vein thrombosis and pulmonary embolism 10
- Extended anticoagulation in cancer-associated venous thromboembolism 10
Combination with Antiplatelet Therapy
When patients with atrial fibrillation require PCI, triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) should be minimized in duration. 11
- The use of ticagrelor or prasugrel as part of triple therapy is discouraged (Class III recommendation) 11
- Clopidogrel is the preferred P2Y12 inhibitor when combining with oral anticoagulation 11
- Dual therapy (P2Y12 inhibitor + anticoagulant without aspirin) should be considered to reduce bleeding risk 11
Key Clinical Decision Points
For Acute Coronary Syndromes with PCI:
- Use prasugrel (Effient) as part of dual antiplatelet therapy with aspirin 2, 12
- Avoid prasugrel if prior stroke/TIA, age ≥75 years (unless high-risk), or weight <60 kg 1
- Alternative P2Y12 inhibitors: ticagrelor or clopidogrel if prasugrel contraindicated 2, 12
For Atrial Fibrillation or VTE:
- Use apixaban (Eliquis) for anticoagulation 9, 13
- Never substitute apixaban for antiplatelet therapy in ACS 11
For Patients Requiring Both Anticoagulation and Antiplatelet Therapy:
- Use apixaban with clopidogrel (not prasugrel) and minimize triple therapy duration 11
- Radial access preferred for PCI to minimize bleeding 8
- Consider proton pump inhibitor for GI bleeding prophylaxis 8
Common Pitfalls to Avoid
Never use prasugrel in patients with prior stroke/TIA—this is an absolute contraindication with demonstrated harm. 4, 1
Do not confuse antiplatelet therapy (prasugrel) with anticoagulation (apixaban)—these address different thrombotic mechanisms. Prasugrel prevents platelet aggregation in arterial thrombosis, while apixaban prevents coagulation cascade activation in atrial fibrillation and venous thrombosis.
Avoid prasugrel pretreatment before knowing coronary anatomy in NSTE-ACS—wait until PCI is confirmed. 7